Historic FDA approval brings first gene therapy for genetic deafness
The first-of-its-kind genetic medicine treats a rare and profound otoferlin-related hearing loss, and will be made available by Regeneron for free in the United States. You have full access to this article via your institution. The US Food and Drug Administration’s approval of Regeneron Pharmaceuticals’ Otarmeni (lunsotogene parvec-cwha) gene therapy for a form of genetic…
